Back to Dashboard

R1979-ONC-2210 (Olympia-5)

Lymphoma•R1979-ONC-2210 (Olympia-5)•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

Odronextamab+ Lenalidomide

Mechanism of Action

CD20+CD3 bispecific Ab

Sponsor

Unknown

Design

III

Control Arm

R2

Criteria

Inclusion Criteria

1.R/R 2.≥1 prior Tx

Age: Phase: III

Exclusion Criteria

Enrollment

Progress0 / 3

Contact Information

Principal Investigator

Unknown

Study Nurse

溫上容

Contact Tel

3998